BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 8
• 9
• 10
• 11
• 12
• 13
• 15
• 16
• 17
• 18
• 19
• 22
• 23
• 24
• 25
• 26
• 29
• 30
• 31

• Press Releases

  Codexis Finalizes Purchase Agreement with Crosswalk Therapeutics for Gene Therapy Assets

  July 1, 2024

   · 

  4 min read
• 

  TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform

  July 1, 2024

   · 

  5 min read
• Press Releases

  Checkpoint Therapeutics Announces Biologics License Application Resubmission for Cosibelimab

  July 1, 2024

   · 

  7 min read
• 

  Sequencing Market Size to Rise at a Healthy 22.21% of CAGR to Reach USD 115.85 Billion by 2033

  July 1, 2024

   · 

  13 min read
• Press Releases

  PharmAbcine’s Phase 1 Clinical Trial of PMC-403 for Neovascular Age-related Macular Degeneration Advances to Both Single-dose of 4mg and Multiple-dose of 3mg

  July 1, 2024

   · 

  4 min read
• Press Releases

  Stryker to announce financial results for its second quarter of fiscal year 2024

  July 1, 2024

   · 

  1 min read
• Biotech Bay

  Circle Pharma files first Investigational New Drug application for first-in-class oral cyclin A/B RxL inhibitor for treatment of advanced solid tumors

  Circle Pharma, a leader in macrocycle drug discovery and development, announced the submission of its first Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CID-078, a first-and-only-in-class cyclin A/B RxL inhibitor.

  July 1, 2024

   · 

  4 min read
• Press Releases

  Precision BioSciences Announces its Addition to the Russell Microcap® Index

  Precision BioSciences, Inc. today announced its addition to the Russell Microcap® Index.

  July 1, 2024

   · 

  9 min read
• FDA

  U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for AKEEGA® (niraparib and abiraterone acetate) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer

  Foundation Medicine, Inc. today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for FoundationOne®Liquid CDx to be used as a companion diagnostic for AKEEGA® (niraparib and abiraterone acetate) from Janssen Biotech, Inc.

  July 1, 2024

   · 

  6 min read
• Drug Development

  ASPIRE-FTD Phase 1/2 Clinical Trial Opens in the U.S. at The Ohio State University Wexner Medical Center

  AviadoBio today announced that its Phase 1/2 ASPIRE-FTD clinical trial is now open and recruiting patients in the United States at The Ohio State University.

  July 1, 2024

   · 

  7 min read